Eli Lilly Reported Results for New Weight-Loss Drug
The pharmaceutical company shared Phase 2 clinical trial data for its combination medication, EloraTZP.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Do you trust that new weight-loss drugs adequately weigh health benefits against potential side effects?
Eli Lilly has released Phase 2 clinical trial results for EloraTZP, a drug combining tirzepatide with the experimental amylin receptor agonist eloralintide. The trial evaluated 367 adults living with obesity and diabetes over approximately one year.
Why it matters
By targeting multiple hormonal pathways, this combination therapy aims to enhance weight loss outcomes for patients struggling with obesity and Type 2 diabetes. The research highlights the potential of using amylin receptor agonists to signal fullness alongside established treatments.
In a study of 367 adults, EloraTZP participants saw weight loss between 13.2% and 23.3% over one year. However, treatment discontinuation rates reached 27% for EloraTZP users, compared to 2.9% for those using Zepbound.
The players
Eli Lilly
An Indianapolis-based pharmaceutical company that researches and manufactures medicines for diabetes, obesity, and other health conditions.
The details
The study, presented in Milan, showed higher gastrointestinal side effects for patients using the combination therapy. Eli Lilly now plans to advance the development of EloraTZP through upcoming Phase 3 clinical trials.
Timeline
September 30, 2026: Eli Lilly released the Phase 2 trial results for EloraTZP.
2030: The company projects annual sales for eloralintide to reach $2.6 billion.
The Big Picture
The presentation at the European Association for the Study of Diabetes annual conference follows the industry trend of vetting obesity treatments against rigorous global endocrinology standards. This study marks a strategic push to expand Eli Lilly's metabolic portfolio by exploring hormonal pathways beyond GLP-1 receptors.
While the combination therapy shows potential for greater weight reduction, patients should be aware of the increased risk of gastrointestinal side effects observed in the trial. High discontinuation rates suggest that balancing efficacy with tolerability will be a key focus as development proceeds.
The takeaway
The trial underscores the complexity of developing multi-pathway weight loss treatments that maintain high patient adherence. Future research will determine if the increased efficacy of such combinations outweighs the challenges associated with higher discontinuation rates.
Further reading
Learn more about the latest innovations in Weight Loss research and clinical developments.
Live Poll
Do you trust that new weight-loss drugs adequately weigh health benefits against potential side effects?
